Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis

Keyphrases

• Vascular Inflammation 100%
• Advanced Atherosclerosis 100%
• Rabbit Model 100%
• Semaglutide 100%
• Activated Macrophages 71%
• SUVmax 57%
• Cellular Metabolism 57%
• Microcalcification 42%
• Placebo 28%
• Positron Emission Tomography-computed Tomography (PET-CT) 28%
• Tracer Uptake 28%
• Atherosclerotic Inflammation 28%
• Placebo Groups 14%
• A1 Receptor 14%
• AIMS™ 14%
• Receptor Agonist 14%
• Glucagon-like 14%
• Vessel Wall 14%
• Attenuation 14%
• 18F-fluorodeoxyglucose (18F-FDG) 14%
• Radiotracer 14%
• FDG-PET Scan 14%
• Multimodality 14%
• Histological Analysis 14%
• Computational Imaging 14%
• Standardized Uptake Value 14%
• New Zealand White Rabbit 14%
• Euthanized 14%
• DOTATATE 14%
• Imaging Analysis 14%
• Target-to-background Ratio 14%
• Tracer Imaging 14%
• Macrophage Activity 14%
• SUVmax Values 14%
• Macrophage Density 14%
• 18F-NaF PET 14%
• Macrophage Metabolism 14%
• Atherosclerotic Calcification 14%

Medicine and Dentistry

• Atherosclerosis 100%
• Positron Emission Tomography 100%
• Vasculitis 100%
• Semaglutide 100%
• Macrophage 85%
• Radioactive Tracer 85%
• Cell Metabolism 57%
• Placebo 42%
• Microcalcification 42%
• Positron Emission Tomography-Computed Tomography 28%
• Sodium Chloride 14%
• Glucagon-Like Peptide-1 Agonist 14%
• Fluorodeoxyglucose F 18 14%
• Copper 64 14%
• Fluorine-18 14%
• Standardized Uptake Value 14%

Immunology and Microbiology

• Atherosclerosis 100%
• Macrophage 100%
• Vasculitis 100%
• Rabbit Model 100%
• Cell Metabolism 66%
• Positron Emission Tomography-Computed Tomography 33%
• Agonist 16%
• New Zealand White (Rabbit) 16%